Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 302 followers
Latest posts
Last updated 10 minutes ago
Opinion/decision on a Paediatric investigation plan (PIP): Ilumetri, tildrakizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000182362
15 minutes ago
Opinion/decision on a Paediatric investigation plan (PIP): Ilumetri, tildrakizumab, decision type: PM...
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0391/2023
about 1 hour ago
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM...
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0492/2023
about 1 hour ago
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM...
Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU - Scientific guideline
about 17 hours ago
Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the...
Explanatory note on the withdrawal of the interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU
about 17 hours ago
Explanatory note on the withdrawal of the interim guidance on enhanced safety...
Human medicines European public assessment report (EPAR): Denosumab Intas, denosumab, Date of authorisation: 17/11/2025, Status: Authorised
about 17 hours ago
Human medicines European public assessment report (EPAR): Denosumab Intas, denosumab, Date of...
CHMP opinions on consultation procedures
about 17 hours ago
CHMP opinions on consultation procedures
Consultation on an ancillary medicinal substance incorporated in a medical device - Gynemed GmbH & Co. KG HSA-containing ART media
about 17 hours ago
Consultation on an ancillary medicinal substance incorporated in a medical device -...
Consideration on core requirements for RMPs of COVID-19 vaccines
about 17 hours ago
Consideration on core requirements for RMPs of COVID-19 vaccines
Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Date of authorisation: 22/11/2018, Revision: 8, Status: Authorised
about 18 hours ago
Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Date...
Availability of medicines before and during crises
about 18 hours ago
Availability of medicines before and during crises